Literature DB >> 13472635

Triethylenethiophosphoramide (thio-tepa) in the treatment of neoplastic disease.

J E ULTMANN, G A HYMAN, C CRANDALL, H NAUJOKS, A GELLHORN.   

Abstract

Entities:  

Keywords:  CYTOTOXIC DRUGS/therapeutic use

Mesh：

Substances：

Year:  1957        PMID： 13472635     DOI： 10.1002/1097-0142(195709/10)10:5<902::aid-cncr2820100507>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  7 in total

1.  Chemotherapy of solid cancer arising from the gastro-intestinal tract.

Authors:  J D HURLEY; E H ELLISON
Journal:  Ann Surg       Date:  1960-10       Impact factor: 12.969

2.  Chemotherapy of cancer.

Authors:  K A NEWTON
Journal:  Postgrad Med J       Date:  1958-12       Impact factor: 2.401

3.  Malignant lymphoma. A report of two contrasting cases in children.

Authors:  L L ALEXANDER
Journal:  J Natl Med Assoc       Date:  1960-07       Impact factor: 1.798

4.  Chemotherapy in Malignant Disease: The Present Position.

Authors:  A E Buckle
Journal:  Postgrad Med J       Date:  1961-06       Impact factor: 2.401

5.  High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: a case report.

Authors:  U M Saarinen; H Pihko; A Mäkipernaa
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

6.  Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies.

Authors:  Diana S Osorio; Ira J Dunkel; Kelly Ann Cervone; Rakesh K Goyal; K M Steve Lo; Jonathan L Finlay; Sharon L Gardner
Journal:  Pediatr Blood Cancer       Date:  2017-09-14       Impact factor: 3.167

7.  Triethylene thiophosphoramide in the treatment of previously hypophysectomised patients with carcinoma of the breast.

Authors:  K J GURLING
Journal:  Br J Cancer       Date:  1959-06       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.